AVEO Gets Complete Response Letter for Tivozanib

The FDA has rejected AVEO’s kidney cancer candidate tivozanib in line with an advisory committee’s recent recommendations. The complete response letter revealed by the company Monday comes two weeks after a key partner backed out of the drug’s development program.
Drug Industry Daily